Abstract:Background Lung cancer has the highest mortality rate among malignancies globally. In addition, due to the growing number of smokers there is considerable concern over its growth. Early detection is an essential step towards reducing complications in this regard and helps to ensure the most effective treatment, reduce health care costs, and increase survival rates. Aims To define the most efficient and cost‐effective method of early detection in clinical practice. Materials and Methods We collected the Information used to write this review by searching papers through PUBMED that were published from 2021 to 2024, mainly systematic reviews, meta‐analyses and clinical‐trials. We also included other older but notable papers that we found essential and valuable for understanding. Results EB‐OCT has a varied sensitivity and specificity—an average of 94.3% and 89.9 for each. On the other hand, detecting biomarkers via liquid biopsy carries an average sensitivity of 91.4% for RNA molecules detection, and 97% for combined methylated DNA panels. Moreover, CTCs detection did not prove to have a significant role as a screening method due to the rarity of CTCs in the bloodstream thus the need for more blood samples and for enrichment techniques. Discussion Although low‐dose CT scan (LDCT) is the current golden standard screening procedure, it is accompanied by a highly false positive rate. In comparison to other radiological screening methods, Endobronchial optical coherence tomography (EB‐OCT) has shown a noticeable advantage with a significant degree of accuracy in distinguishing between subtypes of non‐small cell lung cancer. Moreover, numerous biomarkers, including RNA molecules, circulating tumor cells, CTCs, and methylated DNA, have been studied in the literature. Many of these biomarkers have a specific high sensitivity and specificity, making them potential candidates for future early detection approaches. Conclusion LDCT is still the golden standard and the only recommended screening procedure for its high sensitivity and specificity and proven cost‐effectiveness. Nevertheless, the notable false positive results acquired during the LDCT examination caused a presumed concern, which drives researchers to investigate better screening procedures and approaches, particularly with the rise of the AI era or by combining two methods in a well‐studied screening program like LDCT and liquid biopsy. we suggest conducting more clinical studies on larger populations with a clear demographical target and adopting approaches for combining one of these new methods with LDCT to decrease false‐positive cases in early detection.

Blood-based Biomarkers for Early Diagnosis of Lung Cancer: A Review Article

Blood-based Tumor Markers in Lung Cancer

Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer

Biomarkers in Early Diagnosis and Screening of Lung Cancer

Emerging Non-Invasive Detection Methodologies For Lung Cancer

Circulating Biomarkers for Early Stage Non-Small Cell Lung Carcinoma Detection: Supplementation to Low‐Dose Computed Tomography

Biomarkers for Early Diagnosis, Prognosis, Prediction, and Recurrence Monitoring of Non-Small Cell Lung Cancer

Emerging Strategies in Lung Cancer Screening: Blood and Beyond

Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)

Emerging Biosensing Methods to Monitor Lung Cancer Biomarkers in Biological Samples: A Comprehensive Review

Biomarkers and Lung Cancer Early Detection: State of the Art

Emerging Non‑invasive Detection Methodologies for Lung Cancer (Review)

Research of New Tumor Biomarkers for Early Diagnosis of Lung Cancer

Liquid biopsy for early detection of lung cancer

Blood protein biomarkers in lung cancer

Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies

Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy

Biomarkers of lung cancer for screening and in never-smokers-a narrative review

Advances in early detection of non‐small cell lung cancer: A comprehensive review

Lung Cancer Molecular Mutations and Abnormal Glycosylation As Biomarkers for Early Diagnosis

Advances in circulating tumor cells for early detection, prognosis and metastasis reduction in lung cancer